Trial
NCT00360828
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
—
Condition
Astrocytoma
Intervention
Irinotecan Hydrochloride (HCI) Treatment
Why stopped
Principal Investigator left Moffitt and study had low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-23